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Abstract	
Evidence has emerged for a subpopulation of human T cells that express TLR2, a pattern 
recognition receptor ordinarily found on innate immune cells. A cross-modulation pathway 
between TLR2 and CCR5, a chemokine receptor involved in cell migration, has been 
reported in human monocytes by the Signoret lab. CCR5 is expressed by several subsets 
of T cells and notably takes part in the pathogenesis of cancer and HIV-1 infection. Whilst 
a TLR2/CCR5 double-expressing T cell population has been previously reported, its 
function is unclear, and the possibility of a TLR2/CCR5 communication pathway is yet to 
be explored. Expansion of this population could allow functional characterisation, and 
elucidate the conditions favouring generation of these cells.   
Frozen monocyte-depleted human PBMCs were expanded using 9-day PHA/IL2 
stimulation. TLR2+ T cells were identified by flow cytometry, and were characterised as a 
mixed population of TLR2+ CD25+ cells that can also express CCR5, CD4, CD8, CD45RO 
and FoxP3. This subpopulation was detected after three days of PHA stimulation, but 
could not be expanded in presence of IL2 and disappeared from culture by day 9, 
suggesting a transient cell phenotype. These experiments were repeated with a cell 
preparation from freshly isolated PBMCs; the same subpopulation could be identified, but 
the results suggest that the majority of TLR2+CD25+ cells are also CD45RO+ and CCR5+. 
Following a literature review, alternative stimulation conditions thought to favour TLR2 
expression were tested. As with PHA/IL2, no significant expansion of the TLR2+ CCR5+ 
subpopulation was observed. A downmodulation experiment was carried out assessing 
the impact of TLR2 and CCR5 specific ligands on the cell surface expression of their 
receptors. TLR2 ligand stimulation did not affect CCR5 cell surface levels, indicating that 
receptor regulation on these cells may differ from that of monocytes. However, further 
experiments should be carried out before conclusions are drawn. 
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1. Introduction	
 
1.1 The immune system: an overview 
All vertebrates possess an immune system that allows the recognition and elimination of 
invading pathogens, microorganisms responsible for disease.1 This immune system 
consists of specialist circulating blood cells (leukocytes), immune tissues and organs. 
Leukocytes are actively involved in the response to infection, while immune tissues (e.g. 
bone marrow) and organs (e.g. thymus) are primarily sites of leukocyte production, 
storage, maturation and activation.2 
 
1.1.1 Leukocytes: the specialized cells of the immune system  
Leukocytes are a diverse group of cells that take part in the inflammatory response, a 
process aiming to fight infection and prevent and/or repair tissue damage caused by injury 
or insult to the body.3 Subsets of leukocytes play different roles in the inflammatory 
response; some are responsible for recognising and destroying pathogens, others repair 
tissue damage, and some play a regulatory or modulatory role.4 Additionally, leukocytes 
secrete a wide range of molecules that target pathogens or serve communication-related 
functions. These molecules include antimicrobial peptides, which have direct pathogen-
killing effects, as well as cytokines and chemokines, the chemical messengers 
responsible for leukocyte recruitment, activation and regulation. Cytokines and 
chemokines exert their effects by binding to specific cell-surface receptors, initiating 
intracellular signalling pathways that dictate cell behaviour.5,6 This mechanism allows 
communication, regulating the different stages of the overall immune response.7  Cells 
can be grouped according to the branch of the immune system that they belong to; either 
the innate (non-specific) immune system or the adaptive (antigen-specific) immune 
system. Leukocytes are then further divided into smaller subsets within the two groups 
based upon their function and specific markers they express. Innate leukocytes include 
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neutrophils, monocytes, macrophages and dendritic cells while adaptive leukocytes 
consist of B and T cells; lymphocytes.2 
In broad terms, the innate and adaptive immune responses represent the non-specific 
initial response to infection/tissue damage, and then the pathogen-specific response that 
occurs several days afterwards. However, there is considerable overlap, and 
communication between the cells involved in the two different responses is required for 
effective pathogen clearance.8 (see Figure 1 for an overview of the interactions between 
the innate and adaptive immune response)9 
 
1.1.2   The innate immune response 
The innate immune system provides the initial inflammatory response to infection or tissue 
damage. It allows a rapid response to occur to pathogens without the need for recognition 
of their specific type and without having encountered them before. In the event of 
infection, innate immune cells are able to quickly identify foreign cells by distinguishing 
between self and non-self.10  This is achieved by the recognition of molecules that are 
produced by or expressed on the surface of pathogens, known as pathogen-associated 
molecular patterns (PAMPs). PAMPs are a group of small, highly conserved molecules 
expressed by pathogens but not mammalian cells. They are often essential for the 
survival of a pathogen and can also act as virulence factors, allowing effective 
colonisation of a host organism.11 A notable example is lipotechoic acid (LTA), a molecule 
found on the surface of Gram-positive bacteria, that facilitates adhesion between host and 
bacterial cells.12 As PAMPs are common to large groups of pathogens and are often 
required for cell survival, they allow innate immune cells to successfully distinguish 
between host and pathogen based on a relatively small selection of molecules.  
In addition to foreign cells, damaged or dying cells are also recognised and targeted for 
destruction.  Innate immune cells are sensitive to the presence of molecules released 
during tissue damage or cell death: damage-associated molecular patterns (DAMPs). 
Recognition of PAMPs/DAMPs results in a rapid, antigen-independent response, causing 
the clearance of dead and dying cells as well as pathogens.13 This can be achieved 
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through phagocytosis, the process whereby leukocytes engulf and destroy unwanted 
material, ranging from cell fragments to entire pathogens. This process is enhanced by 
complement, a complex system whereby multiple plasma proteins in the blood assemble 
transmembrane channels (membrane attack complexes or MACs) on the surface of 
damaged or pathogenic cells, compromising their cell membrane.14 As part of this 
cascade, cells can also be coated in complement proteins in a process known as 
opsonisation, marking them for destruction by phagocytes.15  
In order to achieve these effects, innate immune cells utilize a variety of intracellular 
signalling pathways. Recognition of DAMPs and PAMPs is dependent on pattern 
recognition receptors (PRRs).10 PRRs include the Toll-like receptor group (TLRs), a class 
of highly-conserved, single spanning transmembrane receptors present on the surface of 
certain leukocytes including neutrophils, macrophages, dendritic cells and monocytes, all 
of which are phagocytes.16,17 Some TLRs are also found on the membrane of the early 
endosome, a compartment within phagocytes that holds ingested microbial components.18 
Binding of TLRs to DAMPs/PAMPs leads to activation of innate leukocytes, resulting in 
increased cytokine and chemokine production and secretion, which recruits both innate 
and adaptive immune cells into the area.19 
The innate immune response is advantageous in the early stages of inflammation; it 
quickly recognizes a broad spectrum of pathogens, and inhibits their spread. However, it 
is a non-specific response, and relies upon a small group of molecules for pathogen 
recognition. Pathogens lacking certain PAMPs, or possessing mutated versions of the 
molecules are able to evade detection. They may also produce PRR inhibitor molecules 
that block binding of their ligands, preventing pathogen recognition.20  In these cases, the 
innate immune response may be ineffective in entirely eradicating an infection. The 
adaptive immune system can then be employed to provide a pathogen-specific response 
to the infection. This is achieved through cytokine- or chemokine-mediated recruitment of 
adaptive immune cells, as well as through antigen presentation. Certain phagocytic cells 
(e.g. macrophages, dendritic cells) are classed as antigen-presenting cells (APCs). These 
are cells that possess major histocompatibility complex class II (MHCII) molecules, 
membrane receptors that display peptides from the surface of pathogens (antigens) to 
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adaptive immune cells.  This allows recognition of a specific pathogen to occur, resulting 
in the activation of the adaptive immune response. 21  The toll-like receptors also play an 
active part in this process; for example, dendritic cells must first be activated by the 
binding of TLR ligands in order to mature into antigen presenting cells.22 
 
1.1.3 The adaptive immune response 
The adaptive immune response, otherwise known as the specific immune response, is the 
second phase of inflammation. It allows a specialized response to individual pathogens, 
targeting them directly via pathogen-specific antigens.23 This response is mediated by B 
and T cells, which are collectively known as lymphocytes. They originate in the bone 
marrow as common lymphoid progenitor cells; B cells complete their maturation in the 
lymph nodes, whereas T cells mature in the thymus and tonsil.  At this stage, the 
lymphocytes possess microbe-sensing mechanisms with affinity for a single pathogenic 
antigen. This is achieved through random gene recombination, allowing extensive 
diversity within B cell receptors (BCR) on the surface of B cells, and T cell receptors 
(TCR) on the surface of T cells. Inevitably, this process leads to the development of 
autoreactive cells; lymphocytes specific to the antigens expressed by host cells. To 
combat this, B and T cells are “tested” for autoreactivity within their respective maturation 
sites; cells that recognise self-antigen are stimulated to undergo apoptosis (a form of 
programmed cell death) to ensure they do not target host tissues.24  
In terms of function, B cells are primarily responsible for antibody production, which allows 
them to immobilize pathogens as well as highlighting them for destruction by T cells. 
When the B cell is activated via antigen-binding to the BCR and/or stimulation by a helper 
T cell, it begins a process known as clonal expansion, rapid division of the B cell to 
produce large numbers of identical effector cells. These are released into the 
bloodstream, where they commence antibody production.25  Antibodies, or 
immunoglobulins, are glycoprotein molecules with a hypervariable region at one end 
which is able to bind to antigens, as well as a conserved Fc region, that is able to bind to a 
certain class of Fc receptor on other immune cells.26 These antibodies are secreted during 
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the immune response and bind to pathogens; this may neutralize the microbe by blocking 
surface receptors, cause agglutination, whereby antibody-coated microbes are attached 
together and immobilized, or simply mark the pathogen as a target for phagocytosis via 
stimulation of Fc receptors on phagocytic cells.2 
T cells are divided into subsets, and play complex roles in the inflammatory response, 
which will be discussed further below.  
A unique feature of the adaptive immune response is its ability to recognize previously 
encountered pathogens. A small subset of B and T cells specific to a certain pathogen 
remain in circulation beyond the resolution of an infection, and are able to expand if the 
individual is re-infected. These cells are memory cells, and their activation results in a 
rapid response in the event of a second infection by a pathogen.  
 
1.1.4 T cells  
T cells are a diverse group of lymphocytes, which are subdivided into many classes 
relating to their varied functions.27 They mature in the thymus, a lymphoid organ located 
beneath the sternum in humans. 28  This is where T cells develop their T cell receptor, an 
antigen-sensing device that is assembled through rearrangement of the genes that code 
for its structure, analogous to the B cell receptor in B lymphocytes. The thymus also 
serves as the site where appropriate cells are selected; after TCR gene rearrangement, 
they undergo positive selection in the outer layer of the thymus, the thymic cortex, where 
they are offered a peptide bound to an APC. This ensures that they are indeed functional, 
and depending on the class of MHC (class I or class II), they are stimulated to express 
either the CD8 receptor or the CD4 receptor respectively (immature T cells express both). 
29,30 This designates their functional role within the adaptive immune system; CD8 cells are 
classed as cytotoxic or killer T cells, whereas CD4 cells are helper T cells, which are able 
to recruit CD8 cells during infection. Once their purpose has been set, they can progress 
to the negative selection process in the thymic medulla. APCs within the medulla present 
the T cells with self-antigens, deleting cells which are found to be autoreactive, preventing 
their release into the peripheral tissues. 31 
	Figure 1: Interactions between the innate and adaptive phase of an immune response. Blue arrows represent steps in response. 1. DAMPs/PAMPs produced 
by pathogens or damaged cells, respectively, are recognised by antigen-presenting cells via TLRs. 2. These cells are phagocytosed by the APCs. 3. Pathogens are 
destroyed by the release of cytotoxic substances via lysosomes into the endosomal space. 4. Antigens on the pathogen cell surface are processed for presentation 
on the surface of dendritic cells. 5. Antigens are presented to B and T cells via MHCI (CD8 T cells) and MHC II (CD4 T cells and B cells) on the surface of the 
dendritic cells, activating them. 6. B and T cells are activated and expand in number. B cells secrete antibodies. 7. Activated T cells and antibodies are released into 
the bloodstream, and travel to the site of infection. 8. B cells secrete antibodies specific to the pathogen identified by the APCs, neutralising the pathogen and 
flagging it for destruction by CD8+ T cells. CD8+ cytotoxic T cells produce cytotoxic cytokines to destroy pathogens. Activated macrophages from step 3 are also 
recruited to the site of infection by chemokines released by CD4 T cells.  
	 
Once maturation is complete, the naïve T cells reside in lymphoid tissue reservoirs such 
as the lymph nodes, tonsil and spleen. Upon phagocytosis of a foreign pathogen, APCs 
process pathogenic antigens into smaller peptide fragments that are then bound to MHC I 
and II. These fragments are then presented to T cells, until a TCR is found that has affinity 
for the peptide. This activates the T cell, and it undergoes clonal expansion to produce 
large numbers of specific T cells that are then released into the bloodstream. They are 
recruited to the area of inflammation by chemokines released by other leukocytes.32 
Many subsets of CD8 and CD4 T cells exist, each serving a specific function and 
possessing a signature combination of surface receptors (see Figure 2: T cell subsets and 
functions).33 These groups include effector T cells, which are directly involved in the 
immune response, memory T cells, which provide a record of encountered pathogens, 
and modulatory T cells such as regulatory T cells (Tregs) that control the action of other T 
cells as well as other leukocytes.  
	
 
 
Figure 2: T cell subsets. T cells are derived from the same lymphoid progenitor cells as B cells in 
the bone marrow. Growth factors determine the terminal differentiation of T cells into their ultimate 
phenotypes. 
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1.1.5 Regulatory T cells 
Regulatory T cells represent a modulatory subset of the T cell population. They are 
characterised by their expression of the nuclear transcription factor FoxP3 on human T 
cells; the majority of Tregs are CD4-expressing (although some subsets of CD8 Tregs are 
thought to exist); they also possess high surface levels of the activation marker CD25, the 
alpha-chain of the IL-2 receptor.34,35 Their regulatory function allows tolerance of non-
harmful foreign material and reduce tissue damage caused by overexuberant immune 
responses via their anti-inflammatory effect. Tregs are also able to recognise autoreactive 
T cells that have escaped deletion in the thymus, and can destroy aberrant cells via 
granzyme or perforin secretion, causing apoptosis.36  
Regulatory T cells respond readily to the presence of IL-2, a pro-inflammatory cytokine 
produced by other T-cells, meaning that they are activated by the chemokine in areas 
where large numbers of conventional T cells are present.37  This serves to prevent 
excessive numbers of T cells accumulating, and stops any excessive inflammation 
causing unnecessary tissue damage. Control of inflammation is crucial in situations such 
as viral lung infection, where inadvertent destruction of the respiratory membranes can 
have fatal effects.38 
It also allows tolerance of self-antigens to occur, as well as to non-harmful foreign 
particles by suppressing inflammatory events.39  There are many situations where it is not 
advantageous to eliminate non-harmful bacteria. For example, the microbiome in the gut 
is important for micronutrient metabolism as well as providing healthy competition to 
prevent bacteria, such as pathogenic strains of Esterichia coli, from forming harmful 
colonies.40,41 In addition, other commensal organisms like Bacteroides fragilis often 
asymptomatically infect the GI tract.42 An absence of Tregs in this circumstance has been 
found to cause inflammation, leading to the formation of lesions and the onset of colitis.43  
Depletion or dysfunction of Tregs in human and mouse models leads to the development 
of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE) 
and psoriasis vulgaris. Conversely, Tregs have been shown to be recruited by tumours in 
order to help them evade the immune response, with high numbers of Tregs in the tumour 
microenvironment associated with poor disease prognosis.44 
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1.2 T cells and TLR2 
1.2.1 Function of TLR2  
TLR2 is a member of the Toll-like receptor family, a series of receptors that serve to 
recognise PAMPs and initiate a pro-inflammatory response.45,46 Toll-like receptors are a 
set of highly conserved pattern recognition receptors, specialised to recognise a wide 
range of pathogens including bacteria, fungi and viruses. There are ten different classes 
of TLR in humans, which are present on the cell membrane or the on the endosome, the 
space created in phagocytic cells when a pathogen is engulfed and contained before its 
degradation (see Figure 3).  
TLR2 is typically found on cells of the innate immune system, such as monocytes and 
neutrophils, acting as an initial non-specific response to the presence of invading bacteria 
in the body. This leads to the release of inflammatory cytokines, which are responsible for 
numerous inflammatory effects, and are able to activate and regulate the function of T 
cells in the case of infection. These include TNF-α, and members of the interleukin (IL) 
family, including IL-2.47,48 
Dysfunction of the TLR2-mediated recruitment pathway has profound effects on immune 
regulation. In the situation of bacterial presence in the bloodstream (bacteraemia), high 
concentrations of TLR2 ligands produced by bacteria such as LTA, derived from the 
Gram-positive bacterium Staphylococcus aureus, recruit large numbers of TLR2-
expressing leukocytes. This leads to massive systemic inflammation, causing destruction 
of healthy tissues and potentially lethal sepsis.49 In the case of antibiotic-resistant strains 
of bacteria, such as methicillin-resistant S. aureus (MRSA) prognosis is extremely poor, 
and leads to thousands of deaths every year, especially in the developing world where 
access to healthcare is difficult.50,51 
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1.2.2 Evidence for TLR2-expressing T cells 
More recently, evidence has emerged that TLR2 is expressed by subpopulations of T 
cells, both in humans and mice. Regulatory and memory T cells have been reported to 
harbour varying levels of TLR2 on their cell surface. The function of TLR2 in this situation 
is unclear, given that it is primarily associated with the innate immune response.  
One piece of evidence for the role of TLR2 on T cells relates to the receptor’s endogenous 
ligands. TLR2 has many endogenous ligands, including DAMPs such as biglycan, human 
cardiac myosin and the heat shock proteins HSP60 and HSP70. The binding of these 
DAMPs to TLR2 signals that damage has occurred, recruiting immune cells into the area. 
This allows cells of both the innate and adaptive immune response to move into the area 
of inflammation.52  
TLR2-expressing T cells are also known to play a crucial role in the development of 
disease. Wang et al observed an increase in the number of murine Th17 T cells that 
expressed TLR2 during Group A streptococcal infection; Bao et al found that 
Figure 3: Human Toll-like receptors. Toll-like receptors are typically found on the cell or 
endosomal membrane of cells of the innate immune system. They serve to recognise pathogens 
and initiate chemokine signalling that recruits immune cells to sites of infection, or signals for the 
destruction of internalised pathogens.  
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Pseudomonas aeruginosa-derived N-(3-oxododecanyl)-L-homoserine caused an increase 
in RNA and surface expression of TLR2  in human T cells.53,54  Both of these studies 
discuss the role that TLR2 may play in the development of chronic infection and the 
presence of biofilms, suggesting that sepsis resulting from overproliferation of T cells in 
these diseases may be mediated by TLR2.  Another role for TLR2 in chronic infection 
relates to its role in S. aureus infection, specifically in more virulent strains, including 
methicillin-resistant S. aureus (MRSA). Chronic inflammation during MRSA-related sepsis 
is thought to be mediated by the ligation of TLR2 by S. aureus-derived LTA in regulatory 
and Th17 T cells.53  
 
1.2.3 Regulatory T cells and TLR2 
Regulatory T cells are one of the subpopulations of T cells that have been reported to 
express TLR2 in humans and mice.  In terms of functional pathways beyond cell 
recruitment, there is evidence to suggest that TLR2 acts to control expansion and 
proliferation of regulatory T cells in mice, with TLR2 knockout animals experiencing 
significantly reduced numbers of Tregs compared to their wild type counterparts.55  Given 
that TLR2 is able to induce the release of chemotactic chemokines that recruit innate 
immune cells in response to DAMPs and PAMPs, it is probable that it serves the same 
purpose on regulatory T cells. This would result in the accumulation of Tregs in areas of 
inflammation to allow them to offset damage that may be caused to healthy cells. As 
Tregs are known to be activated by the release of the pro-inflammatory cytokine IL2, it is 
likely that signalling via TLR2 serves a similar purpose, allowing recruitment through 
TLR2-mediated chemokine release.56 The fact that the addition of TLR2 ligands has been 
observed to maintain and expand the circulating Treg population adds further weight to 
this theory. Tregs are vital for the mediation of the inflammatory response, and so 
mechanisms for recruiting and retaining them at sites of inflammation must exist for Tregs 
to serve their purpose.  
It is also possible that other organisms are able to hijack this pathway. Most successful 
pathogens have evolved to evade their host’s immune response in order to enhance their 
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own survival. There is evidence to suggest that a range of TLR2 ligands, including 
bacterial lipoprotein (BLP) and the synthetic TLR2 ligand Pam3CSK4, are able to recruit 
and expand Treg numbers.55,57 It is postulated that this induces an immunosuppressive 
effect that is advantageous in bacterial infection and aids pathogen survival. This 
phenomenon is also seen in C. albicans infection in mice, suggesting that TLR2- 
dependent Treg recruitment could play a significant role in the development of chronic 
disease.58  
 
1.3  CCR5 and TLR2  
1.3.1 Role of CCR5  
CCR5 is a G-protein coupled chemokine receptor that ordinarily plays an important role in 
cell migration and activation in inflammation.59 It possesses seven-transmembrane loops, 
associated with a G-protein, allowing downstream signalling in response to external 
stimulus (see Figure 4).  However, it is known to act as a co-receptor for HIV-1 entry into 
cells.60 This has effects on susceptibility to HIV infection in the population; for example, 
individuals homozygous for the Delta32 genetic mutation of the gene encoding CCR5 do 
not express the receptor, and can be exposed to HIV without becoming infected.61 
Additional to this, some CCR5 ligands have been shown to provide anti-HIV action by 
downmodulation of CCR5 on T cells, another area recently explored by the Signoret 
group.62 It is also thought that CCR5 is an important factor in cancer pathogenesis, with 
evidence that it plays a part in recruiting regulatory T cells into tumours to assist in 
immune system evasion, notably in colorectal cancer and nasopharyngeal carcinoma.63,64 
CCR5 is known to be expressed on some memory and regulatory T cells; TLR2 
expression has also been reported in these subsets.65 
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1.3.2  Possibility of a double-expressing T cell population 
It is known that both TLR2 and CCR5 can be expressed by regulatory and memory T 
cells, meaning that a double-expressing population may well exist. However, this has not 
been demonstrated, and the role of a double-expressing population remains unclear.  
A TLR2 and CCR5-expressing population would possess the ability to be recruited to 
areas of inflammation, both by the recognition of PAMPs/DAMPs through TLR2, and via 
CCR5-mediated chemotaxis driven by endogenously-produced chemokines. This would 
be advantageous in the case of Tregs, drawing them to sites of inflammation where they 
are needed to mediate damage caused by effector cells. However, it is more likely that the 
purpose of CCR5 is independent of TLR2 expression.   
CCR5 serves as an essential receptor for regulatory T cells; it is known to be needed for 
recruitment of effector and memory Tregs to areas of inflammation. Additional to this, 
CCR5 is known to play a key role in the suppressive effect of Tregs; notably, Chang et al 
found that CCR5-/- murine Tregs were unable to suppress anti-tumour CD8+ T cells in 
vivo.66 TLR2, however, is only expressed by a small subset of Tregs, and is associated 
with a memory phenotype. These cells patrol the body for an extended period of time, 
Figure 4: CCR5 structure and location. CCR5 is a G-protein-coupled receptor, located in the cell 
membrane of both innate and adaptive leukocytes. It consists of an extracellular N-terminal 
domain and an intracellular C-terminal domain connected by seven transmembrane loops, and 
associates with a G-protein at the C-terminus. 
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providing a long-lasting anti-inflammatory effect, possibly to prevent states of chronic 
inflammation from occurring. Memory regulatory T cells exist in an activated state without 
antigenic stimulus for an extended period of time, originally defined by Loblay et al as 
being greater than 9 months. This allows peripheral tolerance to occur, preventing the 
onset of autoimmune disease. Memory regulatory T cells also exist that have been 
pathogen-stimulated, maintaining their antigen-specificity after the infection has been 
resolved. 67  They are thought to mediate the rapid killing response by CD8+ cells during 
the enhanced secondary response to a previously-encountered pathogen. Further to this, 
it has been found that naive regulatory T cells in mice do not cause suppression of CD8+ 
responses, only T cells that have been previously exposed to pathogenic antigens.68 They 
also allow maternal tolerance of a foetus during pregnancy through sustained suppression 
of an immune response to the non-self-antigens expressed by foetal cells.69 
However, it has been shown that memory Tregs are usually only a transient phenomenon, 
occurring during inflammatory events, and so isolating this population in vitro may present 
a challenge.70 This could explain why a TLR2-expressing T cell population is dependent 
on TCR stimulation, as regulatory T cells only adopt a memory phenotype during periods 
of inflammation and the release of pro-inflammatory TCR ligands. This effect could be 
mimicked by the use of anti-CD3 antibody, a technique used in several papers to induce a 
TLR2-expressing population.  
Evidence for the existence and role of a double-expressing population remains scant. It 
clear that further research is needed to determine whether such a subset of T cells exists. 
If so, it may be possible to elucidate the function of this population and the role it plays 
within the overall immune response.  
 
1.3.3 Evidence for a TLR2- dependent downmodulation pathway for CCR5 
Previous research by the Signoret lab has provided evidence that TLR2 downmodulates 
CC receptors 1,2 and 5 in human monocytes to inhibit their chemotaxis after pathogen 
recognition, allowing monocytes to accumulate at the site of pathogen invasion. However, 
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no such effect was seen with T cells, which were used as a control to further highlight the 
downmodulation seen in monocytes.71 
In contrast to this, McKimmie et al found evidence that TLR2 ligation by bacterial 
lipoprotein does indeed lead to a downregulation of CCR5 mRNA in mouse CD4 T cells.72 
However, the CCR5 receptor differs both structurally and functionally between murine and 
human T cells, meaning that this result needs to be replicated in human T cells before 
conclusions can be drawn.73  
It is also possible that the small numbers of TLR2 expressing T cells present in human 
blood mean that the presence of a downmodulation pathway has been overlooked. The 
large numbers of non-TLR2-expressing T cells present in fresh human blood mean that 
the methods used may not have been sensitive enough to show appreciable 
downmodulation of CCR5 on T cells. As the evidence for a TLR2+ population focuses on a 
small subset of memory and regulatory T cells, looking at them in isolation may reveal that 
a downmodulation pathway does indeed exist. Issues with maintaining Tregs in culture 
also could also be a reason why this population has not been identified. Regulatory T cells 
normally exist in very small numbers in the blood of healthy individuals, and their survival 
is dependent on cell-cell contact in vitro.  Another issue is that regulatory T cell numbers 
are known to decline with age, and vary dramatically between individuals, with numbers 
between 0.6-15% being reported.74,75  
 
1.3.4 Significance of the downmodulation pathway in T cells 
Given that CCR5 is known to be a HIV-1 co-receptor, the presence of a downmodulation 
pathway could potentially present an interesting therapeutic target. If TLR2 ligation does 
indeed lead to the downmodulation of CCR5 from the membrane on some T cells, then 
this could be used to preserve T cell numbers in infected individuals by preventing viral 
entry in Tregs, as recently shown by Hirsch et al.76  Additional to this, evidence has 
emerged that TLR2 plays its own role in the pathogenesis of HIV. Recently, it has been 
reported that HIV-1 replication is enhanced by TLR2 ligation in human CD4+ CCR6+ T 
cells.77 It has also been observed that TLR2 ligation by HIV-1 structural proteins increases 
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the expression of pro-viral RNA, and results in an increase in CCR5 expression in T 
cells.78 This raises interesting questions about the interplay between the two receptors, 
and provides more compelling evidence that a cross-talk pathway indeed exists.  
Drawing this evidence together presents a question: As CCR5 and TLR2 can be 
expressed on regulatory and memory T cells, as well as regulatory memory T cells, then 
we hypothesize that a subset of these cells exists that co-expresses both receptors. If this 
is the case, then does a similar downmodulation pathway to that found in monocytes exist 
in co-expressing T cell populations? 
 
1.4  Project aims 
The aims of this project were to determine 1) whether TLR2-expressing cells are found in 
human blood; 2) whether a subpopulation of double-expressing TLR2+CCR5+ cells can be 
identified; 3) determine the phenotype of such cells as well as the culture conditions that 
favour their growth and finally; 4) test the possibility of a cross-downmodulation between 
TLR2 and CCR5 on these cells.  
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2. Materials	and	methods	
 
2.1  Reagents and antibodies 
Tissue culture reagents and secondary antibodies were purchased from Invitrogen; other 
reagents were from Sigma-Aldrich, unless stated. Purified LTA from S aureus and ultra-
pure lipopolysaccharide (LPS; Escherichia coli 0111:B4) were purchased from Invivogen. 
The CCR5 ligand MIP1b was sourced from Peprotech, and AOP-RANTES was a gift from 
Dr Oliver Hartley.  Antibodies were sourced from multiple manufacturers, detailed in Table 
1. 
2.2  Primary cell isolation and culture 
Fresh peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors 
(from apheresis cones taken from single donors; supplied by the NHS Blood and 
Transplant Service, United Kingdom) by density gradient centrifugation with the use of 
Lymphoprep (Axis-Shield). Monocytes were separated from lymphocytes by adherence to 
gelatine-coated plates, and cultured in RPMI containing 20mM HEPES, 10% fetal bovine 
serum, FBS, (PAA Gold), 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 2mM l-
glutamine.  
The monocyte-depleted supernatant removed from the adherence plates was cultured, as 
well as samples of non-monocyte-depleted PBMCs.  Activated lymphoblasts were 
established from lymphocytes by 3 days of culture in RPMI containing 10% fetal bovine 
serum (PAA Gold), 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 2mM l-glutamine. 
Phytohemagglutinin (PHA) was added to media at a concentration of 5 μg/ml for 3 days of 
culture followed by 9 days of culture in media containing 100 U/mL interleukin-2 (IL-2) 
(PeproTech), added at 3 day intervals (see Figure 5: Fresh blood preparation) 
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Frozen monocyte-depleted PBMCs were prepared using the protocol above and 
transferred on day 0 of culture into freezing medium (90% FBS, 10% dimethylsulfoxide) 
before storage in vapour-phase liquid nitrogen. Cells were defrosted at 37°C in a water 
bath, before transfer into complete RPMI for culture and establishment of lymphoblasts 
using methods detailed above.  
  
Fresh apheresis cone, containing human 
blood 
Isolation of PBMC fraction via 
gradient centrifugation 
Monocytes and monocyte- 
depleted PBMCs 
Total PBMCs 
Figure 5: Fresh blood preparation. Fresh apheresis cones were obtained from the NHS Blood and 
Transplant service. Density gradient centrifugation with Lymphoprep (Axis Shield) was used to 
obtain PBMCs from the blood contained within the cone. The monocyte-depleted fraction was 
obtained from the supernatant of a gelatine adherence plate for use in experiments. Total PBMCs 
were also used in experiments. 
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Antibody clone Specificity Isotype Type Manufacturer 
MC5 CCR5 IgG2a Purified (produced in house) 
OKT3 CD3 IgG2a Purified Abcam 
UCHT1 CD3 IgG1 Purified eBioscience 
T2.5 CD4 IgG2a Purified/FITC conjugated Abcam/Biolegend 
RPA-T8 CD8 IgG1 Purified/FITC-conjugated Biolegend 
3.9 CD11c IgG1 FITC-conjugated eBioscience 
BC96 CD25 IgG1 
Purified/ 
PerCp/Cy5.5 
conjugated 
eBioscience/Caltag 
HI100 CD45RA IgG1 Purified eBioscience 
UCHL1 CD45RO IgG2a Purified eBioscience 
PCH101 FoxP3 IgG2a Biotin-conjugated BD Biosciences 
TALB5 HLA-DR IgG2a Purified eBioscience 
Isotype control Anti-mouse IgG1 IgG1 
Purified/ 
biotin-conjugated 
 
Cell 
Signalling/Novus 
 
Isotype control Anti-mouse IgG2a IgG2a Purified eBioscience 
 
Table 1 :	List of antibodies used in experiments.
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2.3  Cytokine/receptor ligand stimulation 
Stimulation of cells was carried out between days 3-6 (after 3 days culture in PHA) or 
days 6-9 (after 3 days culture in PHA then 3 days culture in IL-2). 24-well tissue culture-
treated plates (Dow Corning) were seeded with cells at a density of 1x106 /ml and 
combinations of the following stimulants were added: 10ng/ml IFN-a, 10 ng/ml S. aureus-
derived LTA, 10ng/ml E. coli-derived lipopolysaccharide (LPS) and 2mg/ml plate-bound 
anti-CD3. Anti-CD3 was bound to plates by addition of UCHT1 or OKT3 monoclonal 
antibodies (Abcam) in phosphate-buffered saline (PBS), followed by a 2 hour incubation at 
37°C to allow the antibody to adhere to the plate. The supernatant was then aspirated 
away, and the plates were washed three times in sterile PBS at 20°C before being 
allowed to dry. Cells and other stimulants were added then directly to the wells, 
suspended in media. For representative combinations of stimulants, see Figure 6: Sample 
stimulation plate.  
 
	
Figure 6: Sample stimulation plate. Anti-CD3 (clone OKT3 or UCHT1) was plate-bound by 
incubation of a 2mg/ml solution in non-tissue culture treated plates before removal and washing 
with PBS.  Cells (fresh total PBMCs or fresh/defrosted monocyte-depleted PBMCs) were added to 
wells suspended in RPMI. Stimulants were added to directly wells at appropriate concentrations 
(see Materials and Methods: Cytokine/receptor ligand stimulation).   
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2.4  Staining for flow cytometric analysis 
Cells were added to non-tissue culture-treated 96 well plates (Dow Corning) at a density 
of 4-10x106 cells/ml suspended in 25µl FACS buffer (PBS with 10% FBS and 0.05% 
sodium azide). 25µl primary antibody solution (5-10µg/ml antibody in 
FACS/permeabilization buffer to give a final concentration of 2.5-5µg/ml) in FACS buffer 
was added per well, then the plate was incubated on ice in the dark for 1 hour. Three 
washes (centrifugation at 1200 RPM for 3 minutes) were carried out before resuspension 
in FACS buffer. Staining with secondary antibodies was carried out using the same 
methods and concentrations as the primary antibodies. 
Cells were then fixed in FACS buffer with 3% paraformaldehyde for 20 minutes or 1% 
formaldehyde overnight before one wash in quenching solution (50mM ammonium 
chloride in PBS), then quenching by resuspension in 100µl of quenching solution 
overnight.  
Intracellular staining for the nuclear transcription factor FoxP3 was carried out by first 
permeabilizing cells in permeabilization buffer (FACS buffer + 0.1% saponin from quillaja 
bark) for 15 minutes, then centrifugation and resuspension in 25µl of permeabilization 
buffer. Biotin-conjugated FoxP3 and biotin-conjugated IgG1 isotype control antibody 
solutions were added to appropriate wells, and incubated for on ice in the dark for 1 hour. 
Three washes were carried out, then cells resuspended in 200µl FACS buffer.  
Flow cytometry was carried out on samples transferred into round-bottomed polystyrene 
tubes on a Becton Dickinson LSRFortessa X-20 flow cytometer (BD Biosciences) and 
results were analysed using FlowJo software (TreeStar). 
 
2.5  Downmodulation experiment 
A downmodulation experiment was carried out as previously described on day 3 of 
culture, after 96 hours of PHA stimulation but before addition of IL-2.62 Briefly, 100µl cells 
at a density of 1x106/ml were added to round-bottomed polypropylene tubes (Falcon), 
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then centrifuged and resuspended in 1ml  binding medium, BM, (100ml stock solution 
made up as 10ml of RPMI-10x (Sigma), 89 ml distilled water and sodium hydroxide 
solution added dropwise to achieve pH ≈ 7). 1ml were added to round-bottomed 
polystyrene tubes (100ml stock solution made up as 10ml RPMI, 1ml HEPES, CCR5-
specific ligand (MIP-1β,100ng/ml or AOP-RANTES, 100ng/ml) and TLR2-specific ligands 
(LTA, 1ng/ml) were added.  The tubes were transferred to a 37°C water bath, and 
incubated for 90 minutes with gentle shaking every 10-15 minutes. The tubes were then 
removed and placed on ice to halt binding, then transferred into a 96-well plate containing 
ice-cold BM and stained as normal for FACS analysis. This experiment was carried out on 
defrosted monocyte-depleted PBMCs as well as monocyte-depleted PBMCs and the 
isolated monocyte fraction for comparison. 
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3.	Results	
3.1 Rationale for use of PHA/IL-2 stimulated PBMCs 
PHA/IL-2 stimulated PBMCs were used as a source of expanding T cells for use in our 
experiments. The rationale for this relates to the reduced proliferative capacity of T cells in 
isolation, and the requirement of accessory cells for expansion. The Signoret lab 
possesses an abundant stock of frozen monocyte-depleted PBMCs, which contain fewer 
monocytes than fresh total PBMCs, but still readily expand in response to PHA/IL2 
stimulation.62	 The defrosted cell population that remained in culture consisted mainly of T 
cells, with other leukocytes such as monocytes, macrophages and B cells also present in 
smaller numbers. These cells were observed to decrease in culture over time, with very 
few non-T cells remaining after 6 days. This makes defrosted monocyte-depleted PBMCs 
a useful source of T cells for initial experiments, although fresh total PBMCs were also 
used for comparison. As the proliferative capacity and survival of T cells has been shown 
to be diminished by cryopreservation, use of fresh total PBMCs allows confirmation of the 
results seen with frozen cells, as well as allowing the influence of accessory cells such as 
monocytes, more accurately reproducing conditions found in vivo.79,80  
The number of monocytes remaining in the monocyte-depleted fraction varies between 
samples, and depends upon experimental technique as well as variation in the number of 
circulating monocytes in the blood of individual donors. Fresh blood is also likely to 
contain other cell populations that do not survive the freezing process, including 
neutrophils, B cells and macrophages. It is possible that the influence that these 
accessory cells have upon T cells in culture could affect their proliferation and receptor 
expression, providing evidence that is more similar to the situation in vivo.  
Regulatory T cells have been observed to exhibit reduced suppressive activity after 
freezing and thawing, and to express lower levels of L-selectin than non-frozen cells, 
suggesting that the freeze/thaw process can cause T cells to behave in a different manner 
than cells in vivo.81 As this is the case, the strategy employed in our experiments was to 
use frozen monocyte-depleted PBMCs to provide initial evidence that could be further 
explored later through the use of fresh total PBMCs. 
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PHA/IL-2 stimulation was chosen as a method of expanding the cells without inhibiting 
CCR5 expression, as is the case when using other standard methods of cell expansion 
such as anti-CD3/anti-CD28, something that has also been observed in the Signoret lab. 
82,83 PHA is a plant-derived lectin that acts as a mitogen, sensitising T cells to IL-2 
stimulation by upregulating expression of the IL-2 receptor, leading to their proliferation in 
culture. It has been observed that monocytes act as accessory cells during PHA/IL2 
stimulation, and are required to present PHA to effectively cross-link the TCR in order to 
expand cells.84 As the populations of interest may consist of small numbers of T cells, it 
was desirable to be able to use either defrosted monocyte-depleted PBMCs or total 
PBMCs subjected to PHA/IL2 stimulation in order to expand the total T cell population.  
The approach taken in our experiments was to compare defrosted monocyte-depleted 
PBMCs using standard expansion with PHA/IL2 to those grown in a variety of stimulation 
conditions that have been reported to enhance TLR2 or CCR5 expression taken from a 
review of literature. Studies reporting methods for increasing the population of TLR2+ cells 
are listed in Table 2A; papers reporting methods of generating CCR5-expressing T cells 
as well as a paper describing a CCR5+ TLR2+ double-expressing subpopulation are 
detailed in Table 2B.  
Flow cytometric analysis was used to define the phenotype of T cell populations of 
interest. These experiments were then repeated on a fresh sample of total PBMCs in 
order to compare the results obtained. A downmodulation experiment was then carried out 
with chemokines known to activate cells via CCR5 (AOP-RANTES and MIP1β) as well as 
the TLR2 ligand LTA in order to examine any differences in expression between the two 
receptors that could potentially be caused by a communication pathway. 
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Study Receptor 
expressed 
by cells 
 
T cells used and selection 
methods 
Culture 
medium 
Conditions of 
culture 
Additions to 
culture medium 
Timings Comments 
Komai-Koma et al, PNAS 
200465 TLR2 
CD45RA+ (naïve)  (and 
CD45RO+ (memory).) 
CD4+ T cells isolated by 
negative selection using MACS 
microbeads (Miltenyi Biotech) 
and sorted by double positive 
selection for CD4+ and CD3+ by 
FACS. 
RPMI 
1640 
+10% 
FCS. 
37°C with 5% CO2- 
cultured with anti-
CD3 and IFN -α 
after selection in 24-
well plates. 
Cultured with 
plate-bound anti-
CD3* (1-5μg/ml) 
and IFN-α (100-
1000 units/ml). 
 
*Induction of TLR2 
expression was 
found to be TCR 
activation- 
dependent. 
Experiments were 
carried out 72hr 
after stimulation 
began. 
IFN-α was found in this study to 
enhance TLR2 expression in CD45RA+ 
T cells. 
(Memory cells were found to 
constitutively express TLR2.) 
Cell-surface TLR2 expression peaked 
between 12 and 72hr after activation 
and continued to remain at high levels 
up to 92hr. 
Nyirenda et al, J Immunol 
201185 TLR2 
CD4+ T cells isolated from 
PBMCs using MACS 
microbeads Treg cell isolation kit 
(Miltenyi Biotec); depletion of 
non-CD4+ T cells then positive 
selection of CD25+. 
Multiple separate 
subpopulations of Tregs (defined 
as being FOXP3+) isolated from 
PBMCs by FACS. 
RPMI 
1640 +5% 
FCS. 
37°C- 2.5x 103 
cells/well (96 well U-
bottom plate) 
Cultured with 
plate-bound anti-
CD3 (1μg/ml) and 
anti- CD28 
(1μg/ml). 
Experiments 
carried out 48 or 
72 hrs after 
stimulation 
began. 
TLR2 was found to be particularly 
highly expressed by 
CD45RA+CD25++  (“resting” Tregs) and 
CD45RA-CD25+++ (“activated” Tregs) 
 
Table 2A:  Techniques for generating TLR2 positive T cells, taken from a review of available literature 
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Study Receptor 
expressed 
by cells 
T cells used and selection 
methods 
Culture medium Conditions 
of culture 
Additions to culture 
medium 
Timings Comments 
Abraham et al, J 
Autoimmun 200886 
Tregs 
(CCR5) 
CD4+ T cells positively 
selected from PBMCs 
(Dynabeads M-450 CD4 
beads)- some were isolated 
from frozen PBMC samples 
RPMI 1640 +10% 
FCS. 
37°C with 
5% CO2. 
Plate bound anti-CD3 
(1μg/ml) , recombinant 
human IL-2 (10U/ml) . 
Incubated with 
plate-bound anti-
CD3 for 5 days, 
then moved to 
uncoated plates 
with the addition 
of human IL-2. 
Cultured for 10-
13 days before 
analysis. 
Stimulation of CD4 T cells with 
anti-CD3 induces regulatory 
phenotype that suppresses self-
reactive PBMCs. 
 
Cells are anergic once regulatory 
phenotype established. 
Schmidt et al, PLOS One 
2016 87 
Tregs 
(CCR5) 
Naive CD4+ T cells were 
positively selected using with 
MACS Naive CD4+ T cell kit 
from fresh PBMCs isolated 
from buffy coats. 
RPMI + 10% FCS 
for one night then 
serum-free X-Vivo 
medium with 1% 
Glutamax and 
100U/ml IL-2 for 
rest of experiment. 
37°C with 
5% CO2. 
Plate bound anti-CD3 
(5μg/ml) and 100U/ml 
IL2 throughout the 
stimulation period. 
0.4 μg/ml anti-CD28 and 
10ng/ml TNF- α1 added 
over 6 day incubation, 
plus10nM all-trans 
retinoic acid (ATRA). 
1 night 
incubation, then 6 
days with 
stimulation.  
FoxP3 expression with 5ng/ml 
TNF- α1 and 0.4 μg/ml CD28 was 
comparable to expression with 
5ng/ml TNF- α1 and 1μg/ml CD28. 
Overnight incubation with RPMI 
carried out to deplete adherent 
monocytes. 
Thibault et al, J Immunol 
2007 88 
TLR2 and 
CCR5 
CD45RA (naive) and CD45 
RO (memory)- negative 
selection using 
immunomagnetic selection. 
Bulk CD4+ T cells were then 
sorted into memory and 
naive cells by negative 
immunomagnetic selection.  
RPMI +10% FCS 37°C with 
5% CO2. 
IL-2 (30 U/ml), 
Pam3Csk4 (5 μg/ml) and 
crosslinked  anti-CD3 
(OKT-3 at 1 μg/ml with 
goat anti-mouse at 5 
μg/ml) or control PHA-
L+ IL-2 
Exposure to 
Pam3Csk4 and/or 
anti-CD3 (clone 
OKT3) for 24 or 
72 hrs after 
selection.  
Stimulation of TLR2 with the 
agonist Pam3Cysk4 resulted in 
expression of CCR5 by naive and 
memory T cells- memory had the 
highest expression, with 10.0% 
expressing when stimulated with 
Pam3Csk4 alone, increasing to 
15.5% of cells expressing with the 
addition of OKT3, compared to 
PHA + IL-2 which resulted in 
13.7% of memory cells expressing 
CCR5.  
 
 
Table 2B: Techniques for generating CCR5+ and CCR5+ TLR2+ T cells taken from a review of available literature.  
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3.2 Monocyte-depleted PBMCs 
In order to identify a TLR2-expressing population, defrosted monocyte-depleted PBMCs 
were stained for flow cytometric analysis, using different combinations of markers to 
confirm phenotypes of TLR2-expressing cells (see Tables 1 and 3). Cells were tested at 
day 0, directly after defrosting, but no TLR2-expression could be detected via flow 
cytometry (not shown).  PHA/IL2 stimulation was then used to assess if TLR2 receptor 
expression could be seen after activation and expansion (see Materials and Methods: 2.2 
Primary cell isolation and culture).  Flow cytometric analysis was carried out at day 3 of 
culture, after stimulation with PHA but before IL2 was added.  T cells were defined as 
CD3+ cells. Live/dead staining was used in order to exclude dead cells from the analysis 
(results not shown). Figure 7 demonstrates the gating strategy for one representative set 
of results of n=12, and shows that TLR2+ T cells could be identified as one subset based 
on TLR2 positive fluorescence signal and their unique forward vs side scatter (FSC vs 
SSC). These cells were classified as subpopulation A. A second CD3+ subpopulation was 
identified, subpopulation B, which was found not to contain significant numbers of TLR2+ 
cells. Both subpopulations were found to be present in all donor samples based on this 
gating strategy, with TLR2-expression limited to subpopulation A. This subpopulation was 
found to be larger in terms of FSC vs SSC than the rest of the T cell population. 
Combined with the fact that no TLR2+ cells could be found at day 0 before addition of 
PHA, this suggests that these cells were activated lymphoblasts rather than naïve T 
cells.89  
 
3.2.1 PHA/IL2 stimulation kinetics 
At day 3, after stimulation with PHA, it was possible to identify TLR2+ T cells in 
subpopulation A. Cells were subsequently expanded for a total of 12 days in PHA/IL2 in 
order to appraise changes in the population over time and the effect of IL-2. CCR5 
expression has been observed to slowly increase over 12 days of stimulation with IL-2. 90 
However, no substantial evidence currently exists for changes in TLR2 expression.  
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Antibody combination Secondary antibodies Purpose
TLR2+CCR5
Anti-mouse IgG1-488+ 
IgG2a-647. Isolation of double-expressing population.
TLR2+CCR5+
LIVE/DEAD
Anti-mouse IgG1-488+ 
IgG2a-647. Confirmation of viability of population.
CD3+TLR2
Anti-mouse IgG1-488+ 
IgG2a-647. Allows gating on CD3+ cells to only consider T cell populations
CD4-FITC+CCR5 Anti-mouse IgG2a-647.
Assessment of proportion of expressing 
population that is CD4+/CD8+
CD4-FITC+TLR2 Anti-mouse IgG1-488.
CD8-PE+CCR5 Anti-mouse IgG2a-647.
CD8-PE+TLR2 Anti-mouse IgG1-488.
CD11c-FITC+CCR5 Anti-mouse IgG2a-647.
Negative control- CD11c is a marker of non-T 
cells (e.g. monocytes).
CD11c-FITC+TLR2 Anti-mouse IgG1-488
CD25 +CCR5
Anti-mouse IgG1-488 + 
IgG2a-647 Assessment of whether T cell population is activated.
CD45RO+TLR2 Anti-mouse IgG1-488+ IgG2a-647
Assessment of whether T cells are memory 
(CD45RO+) or naïve/effector T cells 
(CD45RO-)
Foxp3-biotin+CCR5
Anti-mouse IgG2a-647+ 
streptavidin-PE.
Assessment of whether T cells are regulatory 
phenotype (Foxp3+)
Foxp3-biotin+TLR2
Anti-mouse IgG1-488+ 
streptavidin-PE
Table 3: Summary of antibody combinations used for flow cytometric analysis in the 
experiments presented in the results section. 
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Total population Isolation of singlets 
n= 14 
(Representative 
results from one 
donor shown) 
Isotype control CD3 
Fluorescence intensity 
Isotype control TLR2 
Fluorescence intensity 
Figure 7: Gating strategy for TLR2-expressing T cell subpopulation. Cells were double-
stained for CD3 to define T cell populations, and TLR2. FSC-A vs FSC-H was used to isolate 
singlet populations. A gate was set on CD3+ cells by comparing CD3 fluorescence intensity vs 
SSC to an isotype control. TLR2 fluorescence intensity vs SSC was used to define a TLR2+ T 
cell gate by comparison to an isotype control. The TLR2+ T cell subpopulation was overlaid on a 
scatter plot of FSC vs SSC for the total T cell population in order to set gates for the TLR2+ 
subpopulation (Subpopulation A) and a non-TLR2+ T cell subpopulation (Subpopulation B). 
Subpopulation	A	
31.2%	
Subpopulation	B	
30.2%	
T	cells	
67.9%	
TLR2+	
10.4%	
Singlets	
96.1%	
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Cells were taken from culture every 3 days in order to observe subpopulation size on days 
3,6,9 and 12 of culture. However, through live/dead staining, it was found that the majority 
of the cells (>50%) had died in culture by day 12 (data not shown), and so only days 3, 6 
and 9 were considered.  
 
 
 
 
 
 
 
	
Figure 8 shows variation in TLR2+ cell percentages in the T cell Subpopulation A over 
time. 
When comparing receptor expression kinetics for all the donors over the course of the 9-
day stimulation, it appeared that the percentage of cells expressing TLR2 remains 
relatively stable, despite cell death within the overall population. Upon examination of data 
from 6 different donors, the percentage of TLR2 expression within the small subpopulation 
A follows a similar trend to the percentage represented by these cells in the overall 
population (see Figure 9A). However, Figure 9B demonstrates that the number of live 
cells in Subpopulation A decreases over time, suggesting that the cells are disappearing 
from culture. It appears that whilst the subpopulation itself changes in size, expression of 
the receptors on these cells is not affected by the number of live cells present in culture. 
n.b. As there is overlap between the error bars for the box plots in Figure 9B, no statistical 
significance can be inferred from this set of results in terms of mean numbers of live cells 
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Fluorescence intensity-TLR2 
Figure 8:TLR2 expression in Subpopulation A over 9 days of stimulation. Cells were 
singly- stained for TLR2 expression and analysed using flow cytometry. Gating was carried 
out to define Subpopulation A, using the gating strategy outlined in Figure 7. Histograms of 
stained cells (red histograms) were overlaid on isotype controls (grey shaded histograms) 
and gated to indicate percentage TLR2-expressing cells in Subpopulation A. Experiments 
were carried out for n=12 donors; representative results shown from one donor. 
TLR2+	
49.82%	
TLR2+	
53.14%	
TLR2+	
38.53%	
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for each day over four different experiments. However, it is possible that this downward 
trend may become statistically significant with further repeats of the experiment.  
 
 
 
 
 
 
 
 
After confirming the presence of TLR2+ cells in Subpopulation A, CCR5 expression was 
then examined (Figure 10); CCR5 is known to be widely expressed by CD4+ T cells, so a 
subpopulation of CCR5+cells was expected to be present within the sample.91 Cells 
stained for CCR5 were analysed by flow cytometry and the presence of CCR5+ cells in 
Subpopulation A was assessed using the same FSC/SSC gating strategy described in 
Figure 7 (see Figure 10).   
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Figure 9: TLR2 expression in Subpopulation A over 9 days of stimulation, and percentage live 
cells in Subpopulation A. Cells were single- stained for TLR2 expression and fixable live/dead stain 
was added to assess viability. Subpopulation A was identified using the gating strategy described in 
Figure 7. A. TLR2 expression over a 9 day stimulation with PHA/IL2; each coloured line represents 
results for a single donor. B: Percentage live cells within Subpopulation A. This experiment was carried 
out on n=4 donors. 
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A distinct CCR5-expressing fraction could be seen in Subpopulation A, which raised the 
possibility of a subset of cells expressing both TLR2 and CCR5 being present in the 
Fluorescence intensity- CCR5 expression 
SS
C
 
Isotype control Subpopulation A 
Figure 10: CCR5 expression in Subpopulation A.  Cells were singly- stained for CCR5 
expression and analysed using flow cytometry Subpopulation A was identified using gating 
strategy described in Figure 7. A scatter plot of CCR5 fluorescence intensity vs SSC was 
used to identify CCR5-expressing cells, using an isotype control for comparison. 
Representative results shown from a single donor; this experiment was carried out on n=12 
donors. 
Figure 11: Evidence of double-expressing subpopulation.  Cells were single- stained for TLR2 
expression and analysed using flow cytometry. Subpopulation A was identified using gating strategy 
described in Figure 7.  Quad gates were set on appropriate isotype controls; double-stained cells 
appear in Q2. Representative results shown from a single donor; this experiment was carried out on 
n=12 donors. 
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subpopulation.  Co-staining for CCR5 and TLR2 was used in combination with live/dead 
staining to try and identify a possible double-expressing subpopulation (see Figure 11).	 
After identifying Subpopulation A using our gating strategy (see Figure 7), quad gates 
were applied to a CCR5 and TLR2 double-stained sample, based on appropriate isotype 
controls.  This allowed observation of TLR2+, CCR5+ and CCR5+ TLR2+ cells within 
Subpopulation A. While variations in the size of each subset of cells were seen with 
different donors, a small number of live double-positive cells could consistently be found, 
and makes up 22.9% of Subpopulation A in the example shown in Figure 11 .  
 
 
 
 
 
 
Once this double-expressing population had been identified, kinetics experiments were 
carried out to compare numbers of CCR5+ and CCR5+ TLR2+ cells over time. As with the 
TLR2 kinetics experiments, cells were expanded for 9 days in PHA/IL2, with staining 
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Figure 12: Percentage CCR5 expression and percentage of a double-expressing subpopulation in 
Subpopulation A over 9 days of stimulation. Cells were double- stained for CCR5 and TLR2 
expression and analysed using flow cytometry., Quad gates were set as detailed in Figure 11, and 
percentage expression was recorded over 9 days of stimulation. This experiment was carried out on n=4 
donors. 
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carried out on days 3, 6 and 9. Flow cytometric analysis was used to ascertain the 
percentage of expressing cells present in Subpopulation A compared to the total cell 
population (see Figure 12) 
 
Despite donor variability, we see that there is no expansion of the CCR5+ cell population 
over time, with numbers remaining relatively constant in most cases. The double-
expressing population also appears to remain relatively stable over the 9-day period. 
Whilst a small expansion of the TLR2+ T cell population can be observed, it appears that 
no significant expansion of the CCR5+ TLR2+ T cell population occurs using defrosted 
monocyte-depleted PBMCs. However, as the TLR2+ population is so small, variability 
between donors would have a large effect on cell numbers. It is possible that use of a 
larger number of cells to begin with could lead to expansion of the TLR2+ fraction, allowing 
it to be characterised more effectively. Since Subpopulation A does not appear to expand 
in culture, the implication is that these cells are anergic, and cannot be expanded.92 In 
either case, the use of fresh PBMCs could confirm whether a larger starting population is 
needed. As regulatory T cells have been observed by Abraham et al and Schmidt et al to 
express CCR5, it is possible that they make up some of the subpopulation of interest.86,87 
However, Tregs are thought to expand poorly and exhibit reduced suppressive function 
after defrosting, so the use of fresh cells could elucidate whether this is causing them to 
fail to expand.81 
Day 3 was subsequently chosen as an appropriate day to use for future experiments, as 
the largest CCR5/TLR2 double- positive population could be identified within 
Subpopulation A on this day of culture.  
3.2.2 Characterisation of Subpopulation A 
Further characterisation was carried out to ascertain the phenotypes of cells present 
within the subpopulation. Firstly, CD4 and CD8 staining was carried out to identify whether 
the cells belonged to a cytotoxic or helper T cell lineage. Most evidence relating to a 
TLR2+ population has focused on CD4+ populations, so a majority of CD4+ cells was 
expected.93  
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The T cell fraction of Subpopulation A was identified by gating on a CD3+ population, 
which identified a distinct population based on FSC vs SSC. This population was then 
examined to appraise CD4 vs CD8 expression within the T cells, then was compared to 
the non-TLR2+ Subpopulation B, as well as to the overall cell population (see Figure 13).  
 
 
 
 
 
 
 
 
 
 
Figure 13: CD4/CD8 characterisation of Subpopulation A.  Cells were single-stained for CD4 or 
CD8. Subpopulation A was identified using the gating strategy detailed in Figure 7, and a gate was 
set using FSC vs SSC. CD4+ and CD8+ cells were identified using fluorescence intensity vs SSC, 
compared to isotype controls. This experiment was carried out on n= 6 donors (representative 
results from one donor shown).  
 
 
 
Subpopulation A was found to be a mixed population, composed of mostly CD4+ T cells, 
(defined as either CD4+ or CD3+ CD8- depending upon antibody combinations available at 
the time of the experiment) with the mean expressing fraction on day 3 = 71.9%. CD8 
expression in these populations was substantially lower, with a mean of 25.6% of 
expressing cells in Subpopulation A, and a small number of non-T cells making up the 
remainder (n=6). The proportions of CD4+ and CD8+ cells in Subpopulation A did not differ 
from the CD4/CD8 percentages in the total population (results not shown).  
 
 
Further characterisation was carried out based on this information. TLR2 and CCR5-
expressing cells have been observed to be of regulatory and memory phenotypes; as this 
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is the case, co-staining was carried out to evaluate the expression of the nuclear 
transcription factor FoxP3, a marker of human T cells (see Figure 11), and the surface 
receptor CD25, a component of the IL2 receptor and therefore an activation marker (see 
Figure 12). 
CD45RO was found to be expressed by a large proportion of cells in Subpopulation A on 
day 3 (30.3- 60.1%), suggesting a sizeable memory T cell subpopulation. Furthermore, 
19.6-50.1% of TLR2+ cells were found to co- express CD45RO. Greater variation could be 
seen in FoxP3 expression, ranging from 6.33-73.0% of TLR2+ cells, possibly due to the 
very small numbers of FoxP3 cells present, which caused problems with accurate gating. 
Despite this, a distinct TLR2+ subpopulation can be seen in the FoxP3+ subpopulation, 
although results were still variable, with TLR2+ cells making up 7.55-53.7% of FoxP3 
expressing cells.  
Whilst FoxP3+CCR5+ T cells can be identified (results not shown), the numbers of FoxP3+ 
TLR2+ and TLR2+CCR5+ cells are so small that it was impossible to identify a convincing 
subpopulation that expressed all three receptors through triple staining experiments; the 
number of identifiable triple-positive cells was <50 in all cases (results not shown). This 
meant it was impossible to distinguish between actual triple stained cells and artefact.  
CD25 and TLR2 co-staining was also carried out to assess the activation status of the 
TLR2+ subpopulation (see Figure 12). CD25 was found to be expressed by 72.7-93.5% of 
TLR2+ cells, suggesting that the majority of the subpopulation is made up of activated T 
cells. 
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Figure 14: CD45RO and FoxP3 expression within Subpopulation A.  Cells were double-stained 
for FoxP3/TLR2 and CD45RO on Day 3. The FSC/SSC gating strategy described in Figure 4 was 
used to define Subpopulation A.  Fluorescence intensity vs SSC was used to sequentially gate on 
expressing populations compared to isotype controls. Sequential gating was used to define 
subsets of cells. A. TLR2 expression on CD45RO+ and FoxP3+ cells. CD45RO and FoxP3 
expressing subpopulations represent 40.9% and 27.8% of Subpopulation A respectively.  8.75% of 
CD45RO+ cells express TLR2; 53.7% of FoxP3+ cells express TLR2. B:  Expression of CD45RO or 
FoxP3 on TLR2+ cells. TLR2+ expressing cells represent ~ 25% of Subpopulation A.  47.6% of 
TLR2+ cells express CD45RO; 22.6% of TLR2+ cells express FoxP3. Experiments were carried out 
on n=5 donors; representative results from one donor shown.  
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3.3 Fresh total PBMCs 
	
A major problem with the previous experiments related to the size of the subpopulation of 
interest. Additionally, questions were raised about the viability of regulatory T cells after 
freezing and thawing.  As this was the case, fresh blood samples were used in order to 
ascertain whether a greater number of TLR2+/CCR5+ cells could be obtained and a 
discrete subpopulation identified. These cells were stained with primary antibodies for the 
same markers as in previous experiments in order to examine whether they were in a 
different state of activation. This was especially relevant due to the monocytes now 
present in the blood; most monocytes did not survive after being defrosted. 
 
 
 
 
2. PerCp-
Cy5.5-
coupled  
Mouse anti-
human CD25
2. Alexa Fluor 
488- coupled 
anti-mouse 
IgG1
1. Mouse anti-
human TLR2
Figure 15:CD25 expression within Subpopulation A.  Cells were double-stained for CD25 and 
TLR2. Subpopulation A was identified using the gating strategy described in Figure 7.  A scatter plot 
of fluorescence intensity vs SSC was used to set gates for TLR2+ and CD25+ cells, by comparison to 
isotype controls.  Percentage TLR2+ cells in Subpopulation A= 8.49%; percentage CD25+ cells in 
TLR2-expressing subpopulation= 93.5%. n.b Non-stained control used for comparison to CD25 as no 
appropriate isotype control was available at the time of experiment.  Experiments were carried out on 
n=3 donors; representative results from one donor shown. 
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In the fresh blood samples, a large monocyte population was easily identifiable through 
examining CD11c fluorescence intensity vs SSC, with monocytes making up 10.3% of 
cells in Subpopulation A, compared to 7.64% in the total cell population (see Figure 16). 
This number decreased on Day 6, with 3.92% monocytes remaining in Subpopulation A, 
and 1.1% in the total population. Gating of Subpopulation A was carried out to avoid the 
main monocyte population, based on the distinct FSC vs SSC associated with the T cell 
population. Co-staining with CD3 and/or CD11c were used in order to confirm only T cells 
were being appraised for receptor expression.  
Fluorescence intensity
Fluorescence intensity
Isotype control
Isotype control
CD11c
CD11c Subpopulation A
Total population
Day 3
Fluorescence intensity
Fluorescence intensity
Isotype control
Isotype control
CD11c
CD11c Subpopulation A
Total population
Day 6
Figure 16 Identification of monocytes in fresh blood samples. Cells were singly stained for 
CD11c. FSC-A vs FSC-H was used to isolate singlet populations (not shown). Fluorescence 
intensity vs SSC was used to gate on expressing populations compared to an isotype control 
within Subpopulation A and the total cell population. Numbers represent percentage expression of 
Subpopulation A or total cell population, to demonstrate the percentage of monocytes present in 
each. A gate was applied for the main monocyte population and its location based on FSC vs SSC 
was determined. This was overlaid on a scatter plot of the overall cell population, demonstrating its 
position relative to Subpopulation A. 
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3.3.1: PHA/IL2 stimulation kinetics 
PHA/IL2 stimulation was used to expand fresh total PBMCs and monocyte-depleted 
PBMCs, using the same methods used in expansion of defrosted monocyte-depleted 
PBMCs (see Materials and Methods:  Primary cell culture and isolation). The gating 
strategy described in Figure 7 was used to identify Subpopulation A, which was found to 
contain TLR2+, CCR5+ and TLR2+ CCR5+ cells within the CD3+ subpopulation (see Figure 
11). We observed that the percentage of live cells in the sample increased over the 9 days 
of culture, suggesting that after a recovery period post-isolation, the cells were actively 
expanding in culture (see Figure 17). As with frozen cells, the TLR2+ CCR5+ 
subpopulation was largest on Day 3, with double-expressing cells making up 14.0% of the 
total cell population, notably higher than in the frozen monocyte-depleted PBMCs where 
the numbers rarely exceeded 1% of the total cell population on day 3 (see Figure 9A). 
This is possibly due to better survival of cells in culture than with defrosted PBMCs, 
influence of accessory cells, or the effect of the freeze/thaw cycle on regulatory T cells. 
However, this subpopulation decreased markedly in size over the 9 day stimulation, 
representing 3.71% and 1.21% of the total cell population on days 6 and 9 respectively. 
Total CCR5 expression in Subpopulation A increased considerably by day 9, in 
agreement with previously published data regarding T cells stimulated with PHA/IL2.62 
This suggests that the decreased size of the double-expressing subpopulation is not due 
to cells dying in culture, as the overall number of live cells within Subpopulation A 
increased over the nine days, unlike in the defrosted samples.  
It appears that the double-expressing subpopulation does not expand with PHA/IL2 
stimulation with fresh or defrosted PBMCs. However,it was not possible to carry out a 
triple co-stain with live/dead dye, anti-TLR2 antibody and anti-CCR5 for this particular 
experiment, and so dead cells could not be excluded from the analysis of the double-
stained cells as they had been in the defrosted blood samples. Additionally, due to time 
constraints, this experiment was only carried out on one fresh blood sample. As this is the 
case, this experiment needs to be repeated before conclusions can be drawn. 
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Figure 17: TLR2 and CCR5 expression in a fresh blood sample Cells were double-stained for 
CCR5 and TLR2. Fixable LIVE/DEAD stain was used to assess cell viability; only live cells were 
considered in the analysis. Subpopulation A was identified using the gating strategy described in 
Figure 7. Staining was undertaken at days 3, 6 and 9, before addition of mitogens. Fluorescence 
intensity vs SSC scatter plots were used to identify  CCR5+ and TLR2+ cells in Subpopulation A, 
compared to isotype controls; numbers represent expressing cells as percentage of total cell 
population.  Quad gates were set on appropriate isotype controls to identify double-positive 
CCR5/TLR2 cells (red-outlined quadrants); numbers represent expressing cells as percentage of 
Subpopulation A.  
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Figure 18: CD45RO and FoxP3 expression within Subpopulation A within a fresh blood 
sample.  Cells were double-stained for FoxP3/TLR2 and CD45RO on Day 3. The FSC/SSC gating 
strategy described in Figure 4 was used to define Subpopulation A.  Fluorescence intensity vs SSC 
was used to sequentially gate on expressing populations compared to isotype controls. Sequential 
gating was used to define subsets of cells. A. TLR2 expression on CD45RO+ and FoxP3+ cells. 
CD45RO and FoxP3 expressing subpopulations represent 47.5% and 3.34% of Subpopulation A 
respectively. 14.0% of CD45RO+ cells express TLR2; 23.0% of FoxP3+ cells express TLR2. B:  
Expression of CD45RO or FoxP3 on TLR2+ cells. TLR2+ expressing cells represent ~ 10% of 
Subpopulation A.  89.4% of TLR2+ cells express CD45RO; 0.93% of TLR2+ cells express FoxP3. 
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After examining the kinetics of TLR2 and CCR5-expressing populations, characterisation 
of the cells was carried out to compare with the results from defrosted cells. Cells were 
double-stained for CD45RO and TLR2, and FoxP3 and TLR2. Flow cytometric analysis 
was then undertaken, using the same gating strategy as with defrosted PBMCs (see 
Figure 18).  
Similar results were found to the frozen samples; TLR2+ cells were present in the 
CD45RO+ and FoxP3+ subpopulations, although the number of double-expressing cells as 
a percentage of Subpopulation A was smaller (2.19% CD45RO+ TLR2+ and 0.25% 
FoxP3+ TLR2+). This is most likely due to the higher proportion of other cell types (e.g. 
monocytes) in the fresh sample compared to the frozen cells (see Figure 16). 
CD25 expression was also assessed; again, cells were single stained for CD25 and gated 
after flow cytometric analysis in the same manner as the defrosted samples (see Figure 
19).	 
	
	
Figure 19: CD25 expression within Subpopulation A within a fresh blood sample.  Cells were 
single-stained for CD25 and TLR2.  Subpopulation A was identified using the gating strategy 
described in Figure 7. A scatter plot of fluorescence intensity vs SSC was used to set gates for 
TLR2+ and CD25+ cells, by comparison to isotype controls. Numbers represent the percentage of 
expressing cells within Subpopulation A.  
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Due to the antibodies available in the lab at the time of staining, it was not possible to co-
stain for CD25 and TLR2 with the fresh PBMCs. However, it was found that a similar 
percentage of CD25+ cells could be found in Subpopulation A as in the defrosted 
monocyte-depleted PBMCs. Additionally, a similar percentage of TLR2+ cells and CD25+ 
cells were present in Subpopulation A (11.1% and 12.2% respectively).  It is therefore 
possible that the majority of TLR2+ cells in Subpopulation A are CD25+ in both fresh and 
frozen samples. This means that CD25 could be a significant marker of this 
subpopulation.  
	
3.4 Stimulation experiments 
	
After the identification of a double-expressing subset of cells within Subpopulation 1, 
stimulation conditions were taken from papers that had reported TLR2+ T cell 
subpopulations in order to determine if these cells could be expanded through addition of 
stimulants to cells cultured in 24-well plates (see Tables 2A and 2B). LTA and LPS were 
added as they are known TLR2 ligands; IFN-a was added as it has been observed to 
expand the TLR2+ T cell population. Plate-bound anti-CD3 was added as there is 
evidence that TLR2-expression is TCR stimulation-dependent. Addition of anti-CD3 and 
anti-CD28 is a standard method of expanding PBMCs; however, anti-CD28 has been 
shown to downmodulate CCR5 expression.94 However, anti-CD3 stimulation alone has 
been shown to enhance the T cell population, although it is not known whether this affects 
cell survival in culture due to the lack of a second mitogenic signal.  
Using frozen samples, no significant change in the number of TLR2 expressing cells was 
seen using combinations of these stimulants compared to a non-stimulated control (see 
Figure 20). It appears that the TLR2-expressing population cannot be expanded by these 
methods in a monocyte-depleted PBMC population.  
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In this experiment, it appears that addition of a combination of anti-CD3 and IFNα caused 
a reduction in CCR5 expression, resulting in lower fluorescence intensity than the isotype 
control. There is evidence that IFNα affects the expression of CCR5 on CD4+ and CD8+ T 
cells, and it has been observed to both upregulate receptor expression, which is at odds 
with the evidence from this experiment.95 However, this phenomenon has only been 
observed in one set of experiments; further investigation is needed before conclusions 
can be drawn.  
 
Figure 20: Stimulation experiments using frozen monocyte-depleted PBMCs. Cells were 
stimulated using conditions from a review of the literature, Table 2.  Cell were then double-stained for 
TLR2 and CCR5. Subpopulation A was identified using the gating strategy described in Figure 4. 
Quad gates were set on an isotype control and applied to scatter plots of CCR5 fluorescence intensity 
vs TLR2 fluorescence intensity. 
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3.5 Downmodulation experiments 
A very small subpopulation of TLR2+ CCR5+ cells could be identified in our experiments, 
which could not be expanded with the stimulation methods that we tried. As we were 
unable to increase the number of these cells, we decided to carry out a downmodulation 
experiment on Day 3 with a fresh blood sample to investigate whether any evidence of 
cross-talk could be observed between TLR2 and CCR5. TLR2- and CCR5-specific ligands 
were added in binding medium before incubation for 2 hours to allow receptor binding to 
occur. Cells were placed on ice to halt binding, and staining for flow cytometric analysis 
was carried out (see Materials and methods: Downmodulation experiment). 
CCR5 exhibited a decrease in surface expression upon addition of the CCR5-ligands 
AOP-RANTES and MIP-1b, but no change was seen with the TLR2- ligands LTA or LPS 
(see Figure 21). TLR2 expression was not affected at all by addition of any ligands. This 
means that no evidence could be found in this case for crosstalk between the two 
receptors. However, this experiment was only carried out once, so these results should be 
verified through further investigation.   
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Figure 21: Downmodulation experiment. Cells were removed from culture on Day 3, suspended 
in binding medium and treated with the TLR2 ligand LTA, the CCR5 ligands RANTES or MIP-1b, or 
binding medium alone and incubated for 2 hours to allow ligand binding. Cells were then single-
stained for TLR2 and CCR5. FSC-A vs FSC-H was used to isolate singlet populations (not shown). 
TLR2 fluorescence intensity vs SSC was used to identify the TLR2-expressing T cell subpopulation 
by comparison to an isotype control, and a gate was set on this population based on FSC vs SSC. 
Histograms of each stimulation condition were overlaid on an appropriate isotype control (dotted 
black histograms) and non-treated cells (grey shaded histograms).  
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6.20%	
	 55	
4. Discussion	
	
This project aimed to examine potential TLR2 and CCR5 expressing T cell populations. 
We wished to examine the phenotypes of the cells, and to ascertain the conditions that 
favoured their growth and expansion, before investigating a potential cross-talk pathway 
between the two receptors.  
In order to fulfil these objectives, we used PBMC-derived cells in order to isolate small 
numbers of TLR2+, CCR5+ and TLR2+CCR5 cells within a T cell subpopulation, 
designated Subpopulation A. Receptor kinetics were examined over a period of 9 days in 
culture to investigate changes in receptor expression.  Stimulation experiments were also 
performed to see if Subpopulation A could be expanded through the addition of mitogens, 
cytokines and receptor-ligands taken from a review of literature.  Finally, a 
downmodulation experiment was carried to explore a potential cross-talk pathway.  
The existence of a TLR2+ subpopulation was confirmed through single staining for flow 
cytometry. Co-staining was carried out to define the subpopulation, which was found to 
contain CCR5, CD4, CD8, CD25, CD45RO and FoxP3 positive cells (see Figure 22). 
Triple-staining was also used to try and identify a FoxP3+ TLR2+ CCR5+ regulatory T cell 
population. It was found that 0.96-22.6% of Subpopulation A comprises FoxP3+ TLR2+ 
cells. However, as this percentage represents relatively few cells, and numbers of TLR2+ 
CCR5+ cells are also very small, it was not possible to differentiate cells that co-express 
FoxP3, TLR2 and CCR5 from background fluorescence.  
It was found that TLR2+ cells were activated, as they were only detectable after PHA 
stimulation, a lectin mitogen that cross-links the TCR, resulting in expression of the IL2 
receptor, indicating an activated state of these T cells. Staining for CD25, a component of 
the IL2 receptor, found that 100% of Subpopulation A was CD25+, suggesting that the 
whole population was activated. CD45RO and TLR2 co-staining was carried out, and, 47-
89.4% of TLR2+ cells within Subpopulation A were found to express CD45RO. Despite 
donor variability in expression, it appears that the majority of TLR2+ cells belong to a 
memory T cell population.  
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As TLR2 expression could be associated with expression of CD25, FoxP3 and CD25, it is 
therefore reasonable to conclude that at least some of these cells express all of these 
receptors, although only a minority seem to express FoxP3. Figure 22 summarises 
potential combinations of CCR5, CD45RO, CD25 and FoxP3 within these subpopulations. 
However, more complex staining will need to be carried out in the future out to assess 
whether all four receptors are actually co-expressed on these cells. 
 
 
 
 
 
 
 
 
 
Figure 22: Combinations of possible phenotypes within Subpopulation A. Red text denotes 
marker combinations that have been observed in Subpopulation A; black text denotes potential 
phenotypes that may exist in the subpopulation. 
 
There are two main subsets of cells that appear to be present in the TLR2+ subpopulation; 
memory and regulatory T cells, identified by CD45RO and FoxP3 expression respectively. 
Both of these markers have been observed to be expressed by both CD4+ and CD8+ T 
cells; however, memory and regulatory phenotypes are more commonly associated with 
CD4+ helper T cells.  Expression of TLR2 has been previously reported in these subsets 
(see Table 2). 65,85,86,87,88 Additionally, subsets of regulatory T cells have also been 
reported to express CD45RO;  Table 4 lists phenotypic markers, chemokine receptors and 
transcription factors specific to subsets of regulatory T cells, adapted from a review by 
Rosenblum et al, including CD45RO.96 As the cells in Subpopulation A have been 
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observed to express CD45RO, FoxP3 and CD25, resting, activated effector or memory 
regulatory T cells could be responsible for the phenotypic markers present in this 
subpopulation. FoxP3 and CD45RO have been reported to be expressed by all three 
subsets, and this appears to be the case with our cells; CD25 expression is found in all of 
the cells; however, it is unclear where the CD25 expression we have seen in 
Subpopulation A falls in terms of being high expressing or variable as reported in the 
review from Rosenblum et al.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: List of markers of regulatory T cell subsets, adapted from Rosenblum et al. Green 
cells denote receptor expression and levels observed on cells in Subpopulation A; blue cells 
denote receptor expression observed on cells in Subpopulation A where relative levels of receptor 
expression are unknown. 
Regulatory T cell subset
Resting Activated effector Memory
Phenotypic 
markers
CD25hi CD25 expression variable CD25
hi
CD44hi CD44hi CD44hi
CD45RAhi CD45RAlow CD45RAlow
CD45ROlow CD45ROhi CD45ROhi
CD69low CD69hi CD69 expression unknown
L-selectinhi L-selectinlow L-selectinlow
CD127low CD127low
CD27hi
BCL-2hi
CTLA4low
HLA-DRlow
BCL-2low
CTLA4hi
HLA-DRhi‡
BCL-2hi
CTLA-4hi
HLA-DR expression 
not defined
ICOSlow ICOShi ICOShi
Ki67low Ki67hi Ki67
low
KLRG1hi KLRG1 expression not defined
Chemokine
receptors
CCR7hi CCR7low CCR7low
Transcription 
factors FOXP3
hi FOXP3hi FOXP3hi
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Whilst Subpopulation A appears to express higher levels of CD25 than Subpopulation B, it 
is not clear whether a separate high-expressing subpopulation exists that we have not 
seen in our samples. This means that the specific phenotype of these cells remains 
uncertain, and further investigation should be carried out to more definitively characterise 
this subpopulation.  
CCR5 is known to be expressed by a variety of regulatory T cells, and plays an important 
role in cell migration.97 Notably, whilst TLR2 expression has been observed in regulatory T 
cells, it has not yet been attributed to resting, activated effector or “memory regulatory” T 
cell subsets. 55 We were unable to establish with confidence a FoxP3+ TLR2+ Treg 
subpopulation that also expressed CCR5. However, nearly all TLR2+ cells in 
Subpopulation A for the fresh PBMCs were also CCR5+ at day 3, whereas the percentage 
of FoxP3+ cells within the TLR2+ cells was less than 1%.  CCR5 may well be expressed 
by these TLR2+ regulatory T cells, however, a larger number of cells would need to be 
characterised in the future to assess whether this is the case. 
A large proportion of the TLR2+ cells were CD45RO+, but not FoxP3+, meaning the 
majority of the TLR2+ population fall into the memory phenotype. This has been reported 
by Komai Koma et al and Thibault et al, who both suggest that TLR2 is constitutively 
expressed by CD45RO+ T cells.65,88 Thibault et al also observed that these CD45RO+ 
TLR2+ cells are anergic, which is in line with the results from our experiments, and 
explains why we are unable to expand them.  Co-staining with CD45RO and CCR5 was 
not possible with the antibodies available in the lab; however, in the fresh PBMCs at day 
3, 89% of TLR2-expressing cells in Subpopulation A were CD45RO+. It can therefore be 
inferred that Subpopulation A is TLR2/CD25/CCR5/CD45RO cells. Notably, the 
CD45RO/CD25 phenotype was also reported to express TLR2 and CCR5 by Thibault et 
al.88 However, as this has only been observed in fresh PBMCs from one donor, and to a 
much lesser extent with defrosted cells, this should be investigated further with more fresh 
samples.   
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 It is clear that the small TLR2+ subpopulation in our experiments is a mixture of cells, 
likely to contain TLR2+ CD25+ CCR5+ CD45RO+ cells, and also a very small number of 
TLR2+ CCR5+ CD25+ CD45RO+ FoxP3+ cells. These cells include both CD4+ and CD8+ 
cells, although we did not have the time to investigate the relationship of CD4 and CD8 to 
the other markers; however, a higher proportion of cells seem to be CD4-positive.  
 PHA/IL2 stimulation proved to be the only successful method of generating a significant 
number of TLR2-expressing cells; other methods used, such as stimulation with anti-CD3, 
did not.  Addition of IL2 does not seem to enhance this expression, with the numbers of 
TLR2+ cells declining after day 3, and the TLR2+ CCR5+ subpopulation disappearing from 
culture in fresh samples. It is possible that this relates to cross-linking of the TCR by PHA; 
Komai Koma et al. report that TLR2 expression is TCR-activation dependent.65 However, 
anti-CD3 stimulation also cross-links the TCR, and we did not see the same numbers of 
TLR2-expressing cells when this method was used (see Figure 20). It seems that PHA 
stimulation is able to induce TLR2-expression via a different route. PHA is a plant-derived 
lectin rather than a T cell-specific antigen, and there is evidence that it also activates cells 
via other pathways as well as cross-linking the TCR. PHA has been reported to stimulate 
CD2, with cell expansion occurring in a CD3-independent fashion.98 There is evidence 
that regulatory T cells are dependent on CD2-stimulation in order to differentiate into 
antigen-specific Tregs.99 This causes cell anergy, which could explain the failure of our 
cells to expand. In addition, naïve T cells have been observed to express CD45RO after 
CD2-stimulation.100 This could explain the differences we have observed in PHA and anti-
CD3-stimulated cells. Future experiments should be undertaken to explore whether TLR2 
is expressed when T cells are stimulated with anti-CD2, and if this leads to generation of 
the phenotypes that we observe in our cells.  
The function of these TLR2+ cells is also unclear. Jin et al observed that PAMP binding to 
TLR2 has the ability to activate T cells.101 It is possible that the TLR2 stimulation-pathway 
is an alternative, antigen-independent means of activation for these cells. This could be 
advantageous in the case of regulatory T cells for general antigen-independent 
recruitment to sites of bacterial entry, where they can exert an anti-inflammatory effect on 
other leukocytes, preventing unnecessary tissue damage from occurring. Evidence for this 
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is conflicting; TLR2 has been seen to enhance suppressive function of Tregs, whereas 
Nyirenda et al suggest it reduces suppressive function.102,85 
The case for this pathway in memory T cells is less compelling; by their very nature, 
memory T cells are required to be antigen-specific in order to allow a response to 
previously-encountered antigen. It is possible that their role relates to cell recruitment and 
migration rather than activation, but it is unclear why this would be the case. 
The fact that we were unable to observe downmodulation with the TLR2+CCR5+ T cell 
subpopulation suggests that the role of TLR2 on T cells may differ from TLR2 on 
monocytes, and a communication pathway between TLR2 and CCR5 does not exist in T 
cells. However, it is also possible that we did not have enough cells present in our sample 
to see this effect. Additionally, the downmodulation experiments previously conducted by 
the Signoret lab on monocytes were undertaken between days 7-21; we used PBMCs at 
day 3. It is possible that in the future, with greater number of cells, they could be isolated 
and cultured alone over a longer period of time to see if any downmodulation can be 
seen.  
Another question raised is why this cell population would be anergic. It has been reported 
that this is the case with regulatory and memory T cells. However, the reason for this is 
yet to be elucidated. There is the possibility that the cells are not anergic at all, and the 
reduction in expressing cells is due to T cell plasticity, a phenomenon whereby T cells are 
able to change their phenotype in response to stimulation.103 If PHA stimulation of CD2 is 
what is causing the expression of TLR2 and the expression of memory and regulatory 
phenotypes in these cells, then a lack of stimulation in the following days may cause a 
reversal of this state. In this case, sustained expression of TLR2 would expected with re-
stimulation with PHA or anti-CD2. Further experiments in order to explore this possibility 
should be undertaken in the future.   
At this point, we have established a crude method for the consistent identification of a 
TLR2+ T cell subpopulation. However, there is a clear need to expand these cells in order 
to achieve full phenotyping and functional characterisation.  There are several methods 
that could be attempted in the future to achieve this. As we have established that addition 
of PHA is the best method for generating this subpopulation (potentially via a CD2-
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mediated pathway), it is possible that re-stimulation with PHA or anti-CD2 every 3 days 
could maintain or expand the cells. Other stimulation conditions could also be trialled, as 
we now have a better idea of the phenotype of these cells. IL-7/IL-15 stimulation is of 
particular interest, as it has been shown to generate a memory regulatory T cell, a 
potential phenotype for our TLR2+CCR5+ subpopulation.104  
Isolating these cells for culture alone could also be of benefit; the majority of studies that 
have reported TLR2-expressing T cells have isolated certain subsets, such as CD4+ cells, 
in their experiments (see Tables 2A and 2B). This could be achieved through the use of 
magnetic bead-based cell selection, or use of fluorescence-activated cell sorting, and 
could help to expand the population of interest.  
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4.1 Conclusions 
	
The experiments we have carried out have confirmed TLR2+ and TLR2+ CCR5+ T cells 
exist in our samples, and that these cells are a mixed population. They consist of Tregs, 
memory cells and a mix of CD4+ and CD8+ cells. The majority of TLR2+ cells appear to be 
TLR2/CCR5 double-expressing, and the subpopulation seems to be CD25+, based on 
staining for CD25 as well as the fact that the TLR2+ is only identifiable after PHA 
stimulation.  
We were unable to expand our cells, and this impacted our ability to fully characterise the 
subpopulation. It does appear, however, that this is a transient phenotype that disappears 
from culture. This could be directly caused by the withdrawal of PHA stimulus. 
Alternatively, the temporary nature of the phenotype could be functional; it is possible that 
these cells require further cytokine or antigen stimulation after activation in order to 
proliferate. Observation of the behaviour of this subpopulation in vivo could elucidate the 
cause of this transient phenotype. 
Other groups have reported the existence of this subpopulation, and have reported that it 
other methods of stimulation can be used to induce TLR2 expression, including anti-CD3, 
TLR2 ligands (such as LTA) or IFN-a (see Tables 2A and 2B). However, we were unable 
to see any increase in TLR2 expression with these methods. One explanation for this 
could be our use of live/dead stain in order to discriminate between viable positive cells 
and non-specific antibody binding to dead cells or cell fragments. Fixable live/dead stain 
was not readily available at the time when the papers in Table 2 were published, and 
there is no mention in any of the studies of using staining to assess cell viability. It is also 
possible that TLR2 expression was easier to identify, as the authors of the papers used 
isolated cell subpopulations, such as pure CD45RO+ or CD4+ cells. As the sample size is 
so small, differences in sample quality, and variation in numbers of cell subsets between 
donors has a large impact on our results. In addition, the presence of monocytes made 
the characterisation of the TLR2+ subpopulation more problematic, especially in the fresh 
total PBMCs. The use of isolated cells could resolve these issues, and should be used in 
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the future to see if differences in expression can be seen between PHA/IL2 stimulation 
and the alternative stimulation methods set out in Tables 2A and 2B.  
The significance of this cell population is unclear; however, we do have an idea of some of 
the phenotypes that can be found within the TLR2+ subpopulation. TLR2 is thought to play 
a role in regulating the suppressive function of Tregs, and there is evidence that CCR5 
has a similar function. This could be an important pathway when considering the role of 
regulatory T cells in the pathogenesis of cancer and autoimmune disease. A better 
understanding of the pathways that control the ability of Tregs to suppress other immune 
cells could allow the development of drugs that mediate their anti-inflammatory action. 
Possible uses for this could include disrupting the recruitment of Tregs by tumours, or the 
prevention of the excessive inflammation characteristic of autoimmune conditions.44 
However, careful investigation of these pathways would be needed in order to assess the 
clinical implications and potential for adverse effects caused by the disruption of Treg 
function, given the links between loss of Tregs and autoimmune diseases such as lupus 
erythematosus and rheumatoid arthritis.105 This would  require large numbers of cells 
belonging to the identified subpopulation, and therefore a method for their expansion 
would need to be established. Additionally, this subpopulation does not encompass all of 
the regulatory T cell population, and so may not be a suitable target for systemic therapies 
targeting Treg dysfunction. 
The role of TLR2 on memory T cells is less obvious, and possibly relates to the 
maintenance of their memory function. However, dysfunction of these cells is known to 
cause autoimmune reactions, as the cells continue to cause inflammation long after 
antigen stimulation has ceased.106 Again, an understanding of a communication pathway 
involving TLR2 would be of benefit, and could possibly provide a therapeutic target for the 
regulation and control of dysfunctional cells. 
The downmodulation experiment that we carried out did not produce evidence of a 
communication pathway between TLR2 or CCR5. However, the fact that we found all of 
the TLR2+ cells in our fresh sample to also express CCR5 suggests that there possibly is 
a link between the two receptors. It is possible that there is a pathway that links TLR2 and 
CCR5 expression, but that it is different than the one seen in monocytes. Conversely, 
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when the Signoret lab examined the monocyte downmodulation pathway, the small 
subpopulation of TLR2+ T cells was not detectable when compared to the high levels of 
TLR2 expression on monocytes.62 It is therefore possible that our threshold for detection 
of downmodulation on these T cells is simply not low enough to pick up small changes in 
TLR2 or CCR5 expression, and that a cross-talk pathway does indeed exist for these 
cells. 
It is clear there are many questions raised by our experiments; whilst our methods are 
relatively crude, we have established that this previously-reported subpopulation can 
indeed be found in fresh and frozen PBMCs. Furthermore, we have found CD25 to be a 
possible marker of this subpopulation, and have confirmed that there is expression of 
CCR5, CD45RO and FoxP3 within these cells.  We have been able to build a solid basis 
for future research, and it is likely that further investigation of these cells will yield 
interesting results.  
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5. Abbreviation	list	
APC: Antigen-presenting cell 
BCR: B cell receptor 
BM: Binding medium 
CCR5: CC receptor 5 
CD: Cluster of differentiation (e.g. CD4, CD8) 
DAMP: Damage-associated molecular pattern 
FBS: Fetal bovine serum 
FoxP3: Forkhead box P3 
FSC: Forward scatter 
FSC-H: Forward scatter- height 
FSC-H: Forward scatter- area 
HEPES: (N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid) 
IFNa: Interferon-alpha 
IL: Interleukin (e.g. IL-2) 
LPS: Lipopolysaccharide 
LTA: Lipotechoic acid 
MAC: Membrane attack complex 
MHC: Major histocompatibility complex 
MRSA: Methicillin-resistant Staphylococcus aureus 
PAMP: Pathogen-associated molecular pattern 
PBMCs: Peripheral blood mononuclear cells 
PBS: Phosphate-buffered saline 
PHA: Phytohaemagglutinin 
PRR: Pattern-recognition receptor 
SSC: Side scatter 
SSC-H: Side scatter- height 
SSC-H: Side scatter- area 
Th17: T helper 17 
TCR: T cell receptor 
TLR2: Toll-like receptor 2 
Treg: Regulatory T cell	
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